<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31279839</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin Microbiol Infect</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease.</ArticleTitle><Pagination><StartPage>373</StartPage><EndPage>380</EndPage><MedlinePgn>373-380</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2019.06.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(19)30380-5</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) were responsible for 43.3% (235&#xa0;123/543&#xa0;243) and 24.8% (134&#xa0;607/543&#xa0;243) of all laboratory-confirmed hand, foot and mouth disease (HFMD) cases during 2010-2015 in China. Three monovalent EV71 vaccines have been licensed in China while bivalent EV71/CA16 vaccines are under development. A comparative cost-effectiveness analysis of bivalent EV71/CA16 versus monovalent EV71 vaccination would be useful for informing the additional value of bivalent HFMD vaccines in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a static model parameterized with the national HFMD surveillance data during 2010-2013, virological HFMD surveillance records from all 31 provinces in mainland China during 2010-2013 and caregiver survey data of costs and health quality of life during 2012-2013. We estimated the threshold vaccine cost (TVC), defined as the maximum additional cost that could be paid for a cost-effective bivalent EV71/CA16 vaccine over a monovalent EV71 vaccine, as the outcome. The base case analysis was performed from a societal perspective. Several sensitivity analyses were conducted by varying assumptions governing HFMD risk, costs, discounting and vaccine efficacy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the base case, choosing the bivalent EV71/CA16 over monovalent EV71 vaccination would be cost-effective only if the additional cost of the bivalent EV71/CA16 compared with the monovalent EV71 vaccine is less than &#x20ac;4.7 (95% CI 4.2-5.2). Compared with the TVC in the base case, TVC increased by up to &#x20ac;8.9 if all the test-negative cases were CA16-HFMD; decreased by &#x20ac;1.1 with an annual discount rate of 6% and exclusion of the productivity loss; and increased by &#x20ac;0.14 and &#x20ac;0.3 with every 1% increase in bivalent vaccine efficacy against CA16-HFMD and differential vaccine efficacy against EV71-HFMD, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bivalent EV71/CA16 vaccines can be cost-effective compared with monovalent EV71 vaccines, if suitably priced. Our study provides further evidence for determining the optimal use of HFMD vaccines in routine paediatric vaccination programme in China.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jit</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Modelling and Economics Unit, Public Health England, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Q</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Centre for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Centre for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Centre for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>J T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Electronic address: joewu@hku.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM088558</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bivalent vaccine</Keyword><Keyword MajorTopicYN="N">Cost-effectiveness</Keyword><Keyword MajorTopicYN="N">Coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Hand, foot and mouth disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31279839</ArticleId><ArticleId IdType="mid">NIHMS1046317</ArticleId><ArticleId IdType="pmc">PMC6942242</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2019.06.029</ArticleId><ArticleId IdType="pii">S1198-743X(19)30380-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization Western Pacific Region. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). 2011. 
Available from: http://www.wpro.who.int/publications/docs/GuidancefortheclinicalmanagementofHFMD.pdf.</Citation></Reference><Reference><Citation>National Health Commission of China. Notice of integrating hand, foot and mouth disease into the management of the notifiable diseases [in Chinese]. 2008. 
Available from: http://www.nhfpc.gov.cn/zwgk/wtwj/201304/587bb99411f4491da0b76eeab9d79b01.shtml.</Citation></Reference><Reference><Citation>Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill 2017;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Fact sheets - hand, foot and mouth disease. 2012. 
Available from: http://www.wpro.who.int/mediacentre/factsheets/fs_10072012_HFMD/en/.</Citation></Reference><Reference><Citation>China Food and Drug Administration. List of licensed drugs approved by China food and drug administration in december 2015 [in Chinese]. 2016. 
Available from: http://samr.cfda.gov.cn/WS01/CL0087/142000.html.</Citation></Reference><Reference><Citation>Vaccine National, Serum Institute. The monovalent EV71 vaccine developed by National Vaccine &amp; Serum Institute has been licensed [in Chinese]. 2016. 
Available from: http://www.cnvsi.com/techlistshow.aspx?id=779.</Citation></Reference><Reference><Citation>Wu JT, Jit M, Zheng Y, Leung K, Xing W, Yang J, et al. Routine pediatric enterovirus 71 vaccination in China: a cost-effectiveness analysis. PLoS Med 2016;13:e1001975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792415</ArticleId><ArticleId IdType="pubmed">26978565</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhiyan consulting. China&#x2019;s new vaccine market in-depth survey and market demand forecast report for 2018&#x2013;2024 [in Chinese]. 2018. Beijing.</Citation></Reference><Reference><Citation>Text record of press conference by National Health Commission of China on Apr 9, 2018 [in Chinese] [press release]. Beijing, China: National Health Commission of China; 2018.</Citation></Reference><Reference><Citation>Cai Y, Ku Z, Liu Q, Leng Q, Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014;32:2406&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24657161</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, et al. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice. Hum Vaccin Immunother 2014;10:2885&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5443096</ArticleId><ArticleId IdType="pubmed">25483672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 2014;32:4296&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">24950363</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. Lancet Infect Dis 2014;14:308&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Jit M, Wu JT, Yang J, Leung K, Liao Q, et al. Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. PLoS One 2017;12:e0184266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608208</ArticleId><ArticleId IdType="pubmed">28934232</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, Hsiao VY, et al. Hand, foot, and mouth disease in China: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med 2016;13:e1001958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755668</ArticleId><ArticleId IdType="pubmed">26882540</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M, Grassly NC. Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses. Science 2018;361:800&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6559928</ArticleId><ArticleId IdType="pubmed">30139872</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention. The core information of prevention and control of hand, foot and mouth disease [in Chinese]. 2018. 
Available from: http://www.chinacdc.cn/jkzt/crb/bl/szkb/zstd/201803/t20180326_159976.html.</Citation></Reference><Reference><Citation>Wang W, Song J, Wang J, Li Y, Deng H, Li M, et al. Cost-effectiveness of a national enterovirus 71 vaccination program in China. PLoS Negl Trop Dis 2017;11:e0005899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608421</ArticleId><ArticleId IdType="pubmed">28892475</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014;370:829&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014;370: 818&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2013;381:2024&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Q, Li Y, Cheng K-l, Duan X-w, Li H, Yang L-k, et al. Cost-effectiveness of partial reimbursement for hepatitis B anti-viral drugs in Beijing, China: an analysis based on a retrospective cohort study. The Lancet 2015;386.</Citation></Reference><Reference><Citation>Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, et al. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. Lancet Glob Health 2016;4:e816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5527122</ArticleId><ArticleId IdType="pubmed">27720689</ArticleId></ArticleIdList></Reference><Reference><Citation>National Bureau of Statistics of China. Consumer Price Indices by category (The same month last year = 100) [in Chinese]. 2018. 
[cited 2018 Sep 27]. Available from: http://data.stats.gov.cn/english/easyquery.htm?cn=A01.</Citation></Reference><Reference><Citation>Liu SL, Pan H, Liu P, Amer S, Chan TC, Zhan J, et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol 2015;25:115&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Chen M, Wu W, Yan Q, Zhuo Z, Su X, et al. An emerging and expanding clade accounts for the persistent outbreak of Coxsackievirus A6-associated hand, foot, and mouth disease in China since 2013. Virology 2018;518:328&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29587191</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liao Q, Ooi MH, Cowling BJ, Chang Z, Wu P, et al. Epidemiology of recurrent hand, foot and mouth disease, China, 2008&#x2013;2015. Emerg Infect Dis 2018;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823341</ArticleId><ArticleId IdType="pubmed">29460747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, et al. 2-Year efficacy, immunogenicity, and safety of Vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis 2017;215:56&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of China. Routine paediatric vaccination in different periods in China [in Chinese]. 2016. 
Available from: http://www.nhfpc.gov.cn/zhuz/jbyfykz/201604/eb5596a38e9947b8ad453e8107feb71e.shtml.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>